Although the minimal dose of 17β-estradiol in hormone replacement regimens was originally considered to be 2 mg/day, it is now increasingly accepted that a lower dose of 1 mg/day is effective in protecting women from the detrimental effects of the menopause and has a better safety profile. The aim of this study was to investigate effectiveness and tolerability of minimal dose of hormone replacement therapy (HRT) - femoston 1/5 in postmenopausal women with spine osteopenia. Study comprised 26 postmenopausal women aged 45-65 years with T-score L2-L4 2.5 SD. Treated group consisted of 16 women (average age 54.8+5.59 years and postmenopausal age 6.81+4.59 years) received femoston 1/5 (17β-estradiol 1 mg/ daily continuously combined with dydrogesterone 5 mg/daily) for 12 months. Control group included 10 subjects (average age 56.7+4.11 years and postmenopausal age 11.5+8.09 years). BMD and biochemical parameters were measured at baseline and in 6 and 12 months and climacteric symptoms were assessed at baseline and in 1, 3, 6 and 12 months. The increase in BMD were seen in lumbar spine +5.2%, total proximal femur +2.1% and trochanter +3.1% (р

The aim of this study was to assess the effectiveness of the combined treatment with calcium and middle (400 mg daily) or high doses (800 mg daily) of vitamin D for prevention of osteoporosis in postmenopausal women with osteopenia in spine. Thirty patients, 45-70 years old, were divided into 3 equal groups: the women in the group 1 were treated with vitamin D3 400 IU. and calcium 1000 mg daily; the women in the group 2 received vitamin D3 800 IU and calcium 1000 mg daily; the patients from the group 3 did not receive any supplementation - the control 1 group. A significant increase in BMD was found at lumbar spine (+1.9 % after 6 months, p